IL-22 as a Suppressor of Pancreatic ?-Cell Stress and a Treatment for Diabetes

IL-22 作为胰腺 β 细胞应激的抑制剂和糖尿病的治疗

• 批准号: nhmrc : 1081473
• 负责人: A/Pr Allison Pettit
• 金额: $ 56.98万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/il-22-suppressor-treatment-diabetes/518815
• 关键词: IL; 22; Suppressor; Pancreatic; Cell

Type 2 diabetes occurs when pancreatic beta cells fail to produce enough insulin to control blood sugar levels. We have discovered that the IL-22 protein produced by immune cells protects beta cells from stress. Diabetic mice given IL-22 show restored control of blood sugar levels. The proposed research will take steps to safely introduce IL-22 based therapy into the clinic and gain a deeper understanding of the mechanisms of action of IL-22.

2型糖尿病发生在胰腺β细胞不能产生足够的胰岛素来控制血糖水平时。我们已经发现，免疫细胞产生的IL-22蛋白可以保护β细胞免受压力。给予IL-22的糖尿病小鼠显示血糖水平的恢复控制。拟议的研究将采取措施安全地将基于IL-22的治疗引入临床，并深入了解IL-22的作用机制。